Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: October 7, 2019
Context: The filing serves as a Regulation FD disclosure to provide an update on the interim results of the Company's HOPE-2 clinical trial. The update was delivered via a slide presentation attached as Exhibit 99.1.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of clinical trial updates rather than a financial report.
Material Changes
The material event reported is the release of interim results from the HOPE-2 clinical trial. No financial changes or comparisons to prior periods are detailed in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The Company provided an update on the HOPE-2 clinical trial through a slide presentation available on its investor website and attached to this filing.
Legal Disclaimer: The information contained in this Form 8-K and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. It is not subject to the liabilities of that section and shall not be incorporated by reference into any Securities Act or Exchange Act filing unless expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached slide presentation (Exhibit 99.1) for specific data points regarding the HOPE-2 clinical trial interim results.
- Verify the clinical trial update on the "Investors" section of the Company's website (www.capricor.com).
- Note that this filing does not constitute a formal financial report or contain audited financial data.